肝硬変症治療薬の世界市場:パイプラインレビュー(2018下半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:DATA906A230)
◆英語タイトル:Liver Cirrhosis - Pipeline Review, H2 2018
◆発行会社/調査会社:Global Markets Direct
◆商品コード:DATA906A230
◆発行日:2018年8月14日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:103
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[肝硬変症治療薬の世界市場:パイプラインレビュー(2018下半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Liver Cirrhosis – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis – Pipeline Review, H2 2018, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis – Overview
Liver Cirrhosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Cirrhosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Cirrhosis – Companies Involved in Therapeutics Development
AlfaSigma SpA
Bristol-Myers Squibb Co
Galectin Therapeutics Inc
Gilead Sciences Inc
Grifols SA
International Stem Cell Corp
MallInckrodt Plc
Mina Therapeutics Ltd
Novartis AG
Pharmicell Co Ltd
Rohto Pharmaceutical Co Ltd
VESSL Therapeutics Ltd
Liver Cirrhosis – Drug Profiles
7-E – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADR-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
albumin (human) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCD-800 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986036 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-LC – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emricasan – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXHPC-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTL-CEBPA – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-654 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ornithine phenylacetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit C/EBP-Beta for Gastrointestinal and Respiratory Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin SSD – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate ZSCAN4 for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLY-012 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Cirrhosis – Dormant Projects
Liver Cirrhosis – Discontinued Products
Liver Cirrhosis – Product Development Milestones
Featured News & Press Releases
Jul 10, 2018: Exalenz Bioscience’s Non-Invasive BreathID Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH
Apr 18, 2018: Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
Apr 16, 2018: Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
Apr 04, 2018: Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
Mar 05, 2018: Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences
Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Liver Cirrhosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Liver Cirrhosis - Pipeline by AlfaSigma SpA, H2 2018
Liver Cirrhosis - Pipeline by Bristol-Myers Squibb Co, H2 2018
Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H2 2018
Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2018
Liver Cirrhosis - Pipeline by Grifols SA, H2 2018
Liver Cirrhosis - Pipeline by International Stem Cell Corp, H2 2018
Liver Cirrhosis - Pipeline by MallInckrodt Plc, H2 2018
Liver Cirrhosis - Pipeline by Mina Therapeutics Ltd, H2 2018
Liver Cirrhosis - Pipeline by Novartis AG, H2 2018
Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H2 2018
Liver Cirrhosis - Pipeline by Rohto Pharmaceutical Co Ltd, H2 2018
Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H2 2018
Liver Cirrhosis - Dormant Projects, H2 2018
Liver Cirrhosis - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Liver Cirrhosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

*** 掲載企業 ***

AlfaSigma SpA、Bristol-Myers Squibb Co、Galectin Therapeutics Inc、Gilead Sciences Inc、Grifols SA、International Stem Cell Corp、MallInckrodt Plc、Mina Therapeutics Ltd、Novartis AG、Pharmicell Co Ltd、Rohto Pharmaceutical Co Ltd、VESSL Therapeutics Ltd

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • エッセンシャルオイルのアジア太平洋市場予測2019-2027
    KEY FINDINGSThe Asia Pacific essential oils market is expected to project a CAGR of 8.23% during the forecast period. The rising demands for essential oils, expanding distribution networks, increasing preference for native products, expanding food and beverages industries, rising urban class populat …
  • Immunomedics Inc の製品パイプライン分析2016
    Immunomedics Inc - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Immunomedics Inc - Product Pipeline Review - 2016’, provides an overview of the Immunomedics Inc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics unde …
  • 血液加温器の世界市場
    Long exposure to cold temperature can result in hypothermia condition in which the body temperature drops. Hypothermia increases the risk during surgeries and it also takes a long time to heal. Hence, maintaining the proper temperature is important in order to accelerate the healing process after su …
  • 4-クロロチオフェノールの世界市場予測2019-2024
    It is white crystal and is mainly used as intermediate in pharmaceutical and agricultural chemicals. According to this study, over the next five years the 4-Chlorothiophenol market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx mil …
  • 造血幹細胞移植治療薬の世界市場:治験レビュー
    Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, “Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H1, 2020" provides an overview of Hematopoietic Stem Cell Transplantation Clinical trials scenario. This …
  • ウシ胎仔血清の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2022)
    "Fetal bovine serum is the remained blood fraction after the natural coagulation of blood, which is obtained by centrifugation to remove any remaining red blood cells. Fetal bovine serum is a kind of serum obtained from fetal bovine by stabbing the hearts and collecting the bloods when slaughtering …
  • 有毛細胞白血病治療薬市場:パイプラインレビュー(2019年下半期)
    Hairy Cell Leukemia - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H2 2019, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape. Hairy cell leukemia is a rare, slo …
  • 腫瘍学の世界市場2018
    Oncology Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, unit …
  • 世界の懸濁液濃縮物市場2017
    Notes:Sales, means the sales volume of Suspension Concentrate Revenue, means the sales value of Suspension Concentrate This report studies sales (consumption) of Suspension Concentrate in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/cou …
  • ヤマアラシの世界市場:販売動向2017
    Notes:Sales, means the sales volume of Porcupine Revenue, means the sales value of Porcupine This report studies sales (consumption) of Porcupine in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA906A230 )"肝硬変症治療薬の世界市場:パイプラインレビュー(2018下半期)" (英文:Liver Cirrhosis - Pipeline Review, H2 2018)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。